Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients
Gerd Fätkenheuer(University of Cologne), T.M. Jenkins(Pfizer (United Kingdom)), Gary Layton(University of Geneva), Andreas Plettenburg(Institute for Interdisciplinary Medicine), Lynn McFadyen(Pfizer (United Kingdom)), Schlomo Staszewski(National Institute of Allergy and Infectious Diseases), Frances Hackman(Pfizer (United Kingdom)), John D. Davis(Providence College)
Cited by 43
Related Papers
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by <i>Staphylococcus aureus</i>
|New England Journal of Medicine|2006|1.5k
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|516